1. Introduction {#sec1}
===============

Interleukin-12 (IL-12) is a heterodimeric cytokine that is produced during innate immune response by monocytes, macrophages, dendritic cells (DCs), neutrophils, and B cells \[[@B1], [@B2]\]. The general function of IL-12 is thought to be as an important immunomodulator linking innate recognition of pathogens to development of adaptive immune response \[[@B1], [@B3]\]. Interleukin (IL-12b), also known as p40, is one of the components of IL-12 which covalently combine with p35 (IL-12a) to form mature IL-12 protein. Otherwise, IL-12b could also interact with p19 (IL-23a) to form the other IL-12 family member, IL-23. IL-23 has strong capacity of induction of a novel subset of T cells, the T-helper-17 (Th17) cells. These novel T-helper cells are characterized by production of IL-17 cytokine which is strongly implicated in the pathophysiology of various autoimmune diseases \[[@B4]\]. Owing to the important role of IL-12 and IL-23 during the immune response, IL-12b, the common component of IL-12 and IL-23, might be a candidate gene of autoimmune disease. Indeed, IL-12b has been found to associate with several autoimmune diseases including psoriasis, rheumatoid arthritis, and type 1 diabetes \[[@B5]--[@B9]\].

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multiple organs affected. Autoantibody production, formation of immune complexes and tissue inflammation are the major clinical features of SLE. The reported prevalence of SLE is 20 to 150 cases per 100,000 with a female/male ratio of 9 : 1 \[[@B10], [@B11]\]. The etiology of SLE has not been completely understood, but it is well known that both genetic components and environmental factors contribute to the pathogenesis of SLE \[[@B12], [@B13]\]. Recently, a series of genome-wide association studies (GWAS) were employed for identifying SLE associated genetic variants \[[@B14]--[@B19]\]. These studies provided new insights into the understanding of this complex disease. In the Caucasian populations, it has been suggested that a polymorphism rs6887695 located on IL-12B gene was associated with SLE \[[@B19]\]. Here, we examined this association in Chinese Han population by a recently developed method, unlabeled probe-based high-resolution melting analysis.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

A total of 297 patients (27 males and 270 females; median age 29 years, range 12--55) who fulfilled the American College of Rheumatology criteria for SLE \[[@B20]\] and 351 ethnically matched healthy controls (31 males and 320 females; median age 28 years, range 17--46) were recruited from Shenzhen Hospital, Peking University. The control group had neither family history nor symptoms related to SLE. The study was approved by the institutional review board of the Shenzhen Hospital, and written informed consent was taken from all patients.

2.2. Genotyping {#sec2.2}
---------------

Genomic DNA was isolated from peripheral blood cells by using Innogent genomic DNA extraction kit (Innogent, China) according to manufactory instruction. Genotyping was assayed by high-resolution melting with unlabeled probe as previously described \[[@B21]\]. Briefly, asymmetric PCR reaction was performed in a volume of 20 *μ*L containing 20 ng of genomic DNA, 1 × PCR buffer (Takara, Japan), 200 *μ*M dNTPs, 0.5 U rTaq DNA polymerase (Takara, Japan), 0.05 *μ*M forward primer, 0.5 *μ*M excess reverse primer, and 0.5 *μ*M C3-block probe. The PCR reactions were performed in an S1000 Thermal Cycler (Bio-Rad, USA); the conditions included an initial denaturation at 94°C for 2 min, followed by 45 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 20 s and a final extension at 72°C for 5 minutes. The 10 *μ*L of PCR products was supplied with 1 *μ*L EvaGreen (Bio-Rad, USA) and then subjected to HRM in CFX96 real-time system C1000 Thermal Cycler (Bio-Rad, USA). The samples were first denatured at 95°C for 30 s and rapidly cooled to 40°C for 30 s and then melted from 55°C to 90°C with a 0.3°C/s ramp rate. Melting curves were analyzed with Bio-Rad Precision Melt Analysis software (Bio-Rad, USA). The sequences of the primers for rs6887695 were as follows: forward 5′- GGT AAG TCA GTT TGA GAG AAG CA -3′, reverse 5′- CTA GGT CAC AAG CGT AGT AAA TG -3′, and unlabeled C3-blocked probe 5′- TGT AGT GTA GTG GTC AAT AGT CTG GAT TT -3′.

2.3. Statistical Analysis {#sec2.3}
-------------------------

The SNP was analyzed for an association with the disease by means of comparison of the minor allele frequency (MAF) in patients and controls as well as the constancy of Hardy-Weinberg equilibrium using chi square test or Fisher\'s exact test. The magnitude of association was expressed as odds ratio (OR) with a 95% confidence interval (95% CI). *P* values less than 0.05 were considered statistically significant.

3. Results {#sec3}
==========

3.1. High-resolution Melting Analysis (HRMA) with Unlabeled Probe {#sec3.1}
-----------------------------------------------------------------

High-resolution melting analysis with unlabeled C3-blocked probe was used for genotyping. As shown in [Figure 1](#fig1){ref-type="fig"}, three genotypes (GG, GC, and CC) of SNP rs6887695 (G \> C) were accurately distinguished by the derivative melting curves in the probe region. The derivative melting curves directly from the PCR products were not able to distinguish these genotypes ([Figure 1](#fig1){ref-type="fig"}, right part), and the sensitivity and accuracy of HRMA were dramatically improved using unlabeled probes ([Figure 1](#fig1){ref-type="fig"}, left part). After further analyzing on the normalized melting unlabeled probe region, we were able to discriminate all the genotypes clearly ([Figure 2(a)](#fig2){ref-type="fig"}). The difference curves generated by subtracting of one heterozygote curve displayed a much more clear view for genotype discrimination ([Figure 2(b)](#fig2){ref-type="fig"}). Then, this method was employed to screen our samples in the present study.

3.2. Association of SNP rs6887695 with SLE {#sec3.2}
------------------------------------------

[Table 1](#tab1){ref-type="table"} shows IL-12b rs6887695 genotype and allele frequencies in SLE patients and healthy controls. Genotype frequencies were in Hardy-Weinberg equilibrium in the patients and controls. Statistically significant differences were observed in both genotype and allele frequencies for rs6887695 in the SLE patients as compared with the controls. Minor alleles of rs6887695 (*P* = 0.031, OR 0.78, \[95% CI 0.63--0.98\]) were found to be protective against SLE.

3.3. Association of SNP rs6887695 with the Diagnostic Criteria of SLE {#sec3.3}
---------------------------------------------------------------------

In order to further analyze the possible significance of IL-12b SNPs in SLE, we compared the genotype and allele frequencies of rs6887695 in different diagnostic criteria of SLE. Among the 11 criteria, serositis and neurological disorders in our study were in low incidence and thus were not subjected to statistical analysis.

[Table 2](#tab2){ref-type="table"} showed the analysis of IL-12b SNPs with the clinical symptoms of SLE. We found that rs6887695 was associated with the incidence of arthritis (*P* = 0.033), and minor alleles (C) was protective against arthritis (*P* = 0.013, OR = 0.65, 95% CI = 0.47--0.92). No obvious association was observed between IL-12b SNPs and the incidence of other clinical symptoms.

[Table 3](#tab3){ref-type="table"} showed the association of IL-12b SNPs with the laboratory parameters of SLE. Interestingly, IL-12b SNPs were associated with antinuclear antibody (*P* = 0.032). Minor alleles (C) of rs6887695 were found to exert protective effect on the abnormalities of antinuclear antibody (*P* = 0.022, OR = 0.68, 95% CI = 0.49--0.95). IL-12b SNPs were irrelevant to other laboratory parameters of SLE.

4. Discussion {#sec4}
=============

Genotyping is an elementary method for SNP analysis. High-resolution melting analysis (HRMA) is a cost-effective and high throughput method for SNP genotyping \[[@B22]--[@B24]\]. However, it is sometimes difficult to distinguish SNPs of A/T or G/C (G/C in our case), which make up about 16% of human SNPs, because such SNPs cause only almost undetectable Tm shift (less than 0.4°C). Unlabeled probe melting analysis is a modified HRMA in which a \~30 bp C3-blocked probe is used to target the SNP of interest during the melting. A single-base-pair difference in such a short probe could result in a significant Tm shift (e.g., 3-4°C). As shown in our study, we can discriminate almost all the SNPs in a more accurate and reliable manner using unlabeled probe melting analysis. Thus, the technology of HRMA with unlabeled probe is strongly recommended for studying genetic components of complex diseases such as SLE.

The association of IL-12b with several autoimmune diseases has been well revealed \[[@B5]--[@B9]\]. SLE is a typical chronic autoimmune disease caused by dysregulation of immune system. As a common subunit of IL-12 and IL-23, IL-12b could participate in regulation of several important autoimmune responses especially in Th1 cell maturation and Th17 cell development \[[@B1], [@B4]\]. However, there is little evidence to suggest that IL-12b was associated with disease risk of SLE up to now. In present study, we confirmed that SNP rs6887695 in the gene IL-12b was associated with SLE in the Mainland Chinese Han population, which replicated the findings from a GWAS study in Caucasian population \[[@B19]\], while in a previous study, two SNPs located in the promoter and 3′UTR region of IL-12b gene, respectively, exhibited no association with the susceptibility of SLE in Spanish population \[[@B25]\]. The discrepancy in these findings may be explained by the fact that different SNPs located on IL-12b gene were examined in these studies. The SNP rs6887695 was reported to be associated with psoriasis which is also caused by dysregulation of autoimmune system \[[@B9]\]. Exploring the association of IL-12b with disease risk of SLE in our and others\' work could provide us with a common genetic background for autoimmune disease.

In this study, we also analyzed the association of SNP rs6887695 with different diagnostic criteria of SLE. The potential role of rs6887695 in SLE was further proved by its association with some of the clinical symptoms (arthritis) and laboratory parameters (antinuclear antibody) of SLE. The minor allele (C) of rs6887695 was found to be protective against such diagnostic criteria, indicating the aspects through which rs6887695 exerts protective effect on the risk of SLE. This also implies that, at least in Chinese mainland population, rs6887695 in IL-12b gene may not only be a risk factor specific to SLE, but also might be a contributor to the severity of this autoimmune disease. However, it is not clear why rs6887695 has association with such particular parameters. In the future, the underlying mechanism of rs6887695 in SLE or other autoimmune diseases remains to be more extensively studied.
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![Derivative melting curves of unlabeled probes and amplicon for genotyping of SNP rs6887695. Three genotypes (GG, GC and CC) were discriminated as indicated in probe region.](IJR2012-724872.001){#fig1}

![Normalized melting curves and difference curves of unlabeled probe region for genotyping of SNP rs6887695. (a) The melting curve was presented after normalization. Wild type GG genotype showed the lowest melting temperature since there was completely mismatch between the unlabeled probe and wild type. (b) The difference curves were obtained by subtracting each curve from one heterozygote (GC) curve. Three genotypes (GG, GC, and CC) were shown as indicated.](IJR2012-724872.002){#fig2}

###### 

Genotype and allele frequencies of IL-12b SNP rs6887695 in SLE cases and controls\*.

                             Genotype frequency, no. (%)   Allele frequency, no. (%)                                                              
  -------------------- ----- ----------------------------- --------------------------- ----------- ------------ ------------ ------------ ------- -------------------
  Genotype or allele         GG                            GC                          CC                       G            C                    
   Cases               297   107 (36.0)                    153 (51.5)                  37 (12.5)   0.019        367 (61.8)   227 (38.2)   0.031   0.78 (0.63--0.98)
   Controls            351   114 (32.5)                    164 (46.7)                  73 (20.8)   392 (55.8)   310 (44.2)                        

\*SNP: single-nucleotide polymorphism; SLE: systemic lupus erythematosus; OR: odds ratios; 95% CI: 95% confidence interval.

###### 

Association of IL-12b SNP rs6887695 with clinical symptoms in SLE patients\*.

  ----------------------------------------------------------------------------------------------------------------------------------------
                           Genotype frequency, no. (%)         Allele frequency, no. (%)                               
  ------------------ ----- ----------------------------- ----- --------------------------- ------- ----- ----- ------- -------------------
  Genotype\                GG                            GC    CC                                  G     C             
  or allele                                                                                                            

  Total cases        297   107                           153   37                                  367   227           

  Rash                                                                                                                 

   Positive          161   59                            83    19                          0.923   201   121   0.728   0.94 (0.68--1.31)

   Negative          136   48                            70    18                          166     106                 

  Photosensitivity                                                                                                     

   Positive          90    32                            47    11                          0.987   111   69    0.969   1.01 (0.70--1.44)

   Negative          207   75                            106   26                          256     158                 

  Arthritis                                                                                                            

   Positive          181   74                            90    17                          0.033   238   124   0.013   0.65 (0.47--0.92)

   Negative          116   33                            63    20                          129     103                 

  Oral ulcer                                                                                                           

   Positive          74    27                            39    8                           0.884   93    55    0.761   0.94 (0.64--1.38)

   Negative          223   80                            114   29                          274     172                 
  ----------------------------------------------------------------------------------------------------------------------------------------

\*SNP: single-nucleotide polymorphism; SLE: systemic lupus erythematosus; OR: odds ratios; 95% CI: 95% confidence interval.

###### 

Association of IL-12b SNP rs6887695 with laboratory parameters in SLE patients\*.

  -------------------------------------------------------------------------------------------------------------------------------------
                         Genotype frequency, no. (%)   Allele frequency, no. (%)                                    
  ---------------- ----- ----------------------------- --------------------------- ---- ------- ----- ----- ------- -------------------
  Genotype\              GG                            GC                          CC           G     C             
  or allele                                                                                                         

  Total cases      297   107                           153                         37           367   227           

  Hematological\                                                                                                    
  disorders                                                                                                         

   Positive        187   63                            98                          26   0.429   224   150   0.216   1.24 (0.88--1.76)

   Negative        110   44                            55                          11   143     77                  

  Proteinuria                                                                                                       

  ≥0.5 g/24 h      101   35                            52                          14   0.851   122   80    0.617   1.09 (0.77--1.55)

   \<0.5 g/24 h    196   72                            101                         23   245     147                 

  Antinuclear\                                                                                                      
  antibody                                                                                                          

     ≥1 : 320      168   67                            87                          14   0.032   221   115   0.022   0.68 (0.49--0.95)

   \<1 : 320       129   40                            66                          23   146     112                 

  Anti-DNA                                                                                                          

   Positive        189   72                            97                          20   0.352   241   137   0.191   0.80 (0.57--1.12)

   Negative        108   35                            56                          17   126     90                  

  Anti-nRNP                                                                                                         

   Positive        81    31                            41                          9    0.846   103   59    0.581   0.90 (0.62--1.31)

   Negative        216   76                            112                         28   264     168                 

  Anti-Smith                                                                                                        

   Positive        68    24                            37                          7    0.783   85    51    0.845   0.96 (0.65--1.43)

   Negative        229   83                            116                         30   282     176                 

  Anti-Ro\                                                                                                          
  (SSA)                                                                                                             

   Positive        118   43                            61                          14   0.968   147   89    0.837   0.97 (0.69--1.35)

   Negative        179   64                            92                          23   220     138                 

  Anti-La\                                                                                                          
  (SSB)                                                                                                             

   Positive        72    25                            38                          9    0.963   88    56    0.848   1.04 (0.71--1.53)

   Negative        225   82                            115                         28   279     171                 

  C3 and C4                                                                                                         

   Decrease        133   49                            79                          15   0.399   177   109   0.960   0.99 (0.71--1.38)

   Normal          164   58                            74                          22   190     118                 
  -------------------------------------------------------------------------------------------------------------------------------------

\*SNP: single-nucleotide polymorphism; SLE: systemic lupus erythematosus; OR: odds ratios; 95% CI: 95% confidence interval.
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